Y
Yi Huang
Researcher at Houston Methodist Hospital
Publications - 9
Citations - 601
Yi Huang is an academic researcher from Houston Methodist Hospital. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 8, co-authored 8 publications receiving 536 citations. Previous affiliations of Yi Huang include Third Military Medical University.
Papers
More filters
Journal ArticleDOI
An injectable nanoparticle generator enhances delivery of cancer therapeutics
Rong Xu,Rong Xu,Rong Xu,Guodong Zhang,Guodong Zhang,Junhua Mai,Junhua Mai,Xiaoyong Deng,Xiaoyong Deng,Xiaoyong Deng,Victor Segura-Ibarra,Suhong Wu,Jianliang Shen,Haoran Liu,Zhenhua Hu,Lingxiao Chen,Yi Huang,Eugene J. Koay,Eugene J. Koay,Yu Huang,Yu Huang,Jun Liu,Joe Ensor,Elvin Blanco,Xuewu Liu,Mauro Ferrari,Mauro Ferrari,Haifa Shen,Haifa Shen +28 more
TL;DR: Compared to its individual components or current therapeutic formulations, iNPG-pDox shows enhanced efficacy in MDA-MB-231 and 4T1 mouse models of metastatic breast cancer, including functional cures in 40–50% of treated mice.
Journal ArticleDOI
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery
Haifa Shen,Haifa Shen,Cristian Rodriguez-Aguayo,Rong Xu,Vianey Gonzalez-Villasana,Junhua Mai,Yi Huang,Guodong Zhang,Xiaojing Guo,Litao Bai,Guoting Qin,Xiaoyong Deng,Qingpo Li,Donald R. Erm,Burcu Aslan,Xuewu Liu,Jason Sakamoto,Arturo Chavez-Reyes,Hee Dong Han,Anil K. Sood,Mauro Ferrari,Mauro Ferrari,Gabriel Lopez-Berestein +22 more
TL;DR: Treatment of SKOV3ip2 tumor mice with MSV/EphA2 biweekly for 6 weeks resulted in dose-dependent reduction of tumor weight and number of tumor nodules and inhibited growth of HeyA8-MDR tumors, which were otherwise resistant to docetaxel treatment.
Journal ArticleDOI
Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells.
Joy Wolfram,Krishna Suri,Yi Huang,Roberto Molinaro,Carlotta Borsoi,Bronwyn Scott,Kathryn Boom,Donatella Paolino,Massimo Fresta,Jianghua Wang,Mauro Ferrari,Christian Celia,Haifa Shen +12 more
TL;DR: Liposomal celastrol can decrease the viability of prostate cancer cells, while eliminating the need for toxic solubilising agents.
Journal ArticleDOI
Multistage Vectored siRNA Targeting Ataxia‐Telangiectasia Mutated for Breast Cancer Therapy
Rong Xu,Yi Huang,Junhua Mai,Guodong Zhang,Xiaojing Guo,Xiaojing Guo,Xiaojun Xia,Eugene J. Koay,Guoting Qin,Donald R. Erm,Qingpo Li,Xuewu Liu,Mauro Ferrari,Mauro Ferrari,Haifa Shen,Haifa Shen +15 more
TL;DR: Results indicate that MSV/ATM is biocompatible and efficacious in inhibiting tumor growth, and that further preclinical evaluation is warranted for the development of MSV /ATM as a potential therapeutic agent.
Journal ArticleDOI
Bone marrow endothelium-targeted therapeutics for metastatic breast cancer
Junhua Mai,Yi Huang,Yi Huang,Chaofeng Mu,Guodong Zhang,Rong Xu,Xiaojing Guo,Xiaojing Guo,Xiaojun Xia,David E. Volk,Ganesh L.R. Lokesh,Varatharasa Thiviyanathan,David G. Gorenstein,Xuewu Liu,Mauro Ferrari,Mauro Ferrari,Haifa Shen,Haifa Shen +17 more
TL;DR: Targeting the overexpressed E-selectin provides an effective approach for tissue-specific drug delivery to the bone marrow and significantly extended survival of mice with MDA-MB-231 bone metastasis.